Computationally guided high-throughput design of self-assembling drug nanoparticles
Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug-...
Saved in:
Published in: | Nature nanotechnology Vol. 16; no. 6; pp. 725 - 733 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Nature Publishing Group UK
01-06-2021
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug-loading capacities of up to 95%. There is currently no understanding of which of the millions of small-molecule combinations can result in the formation of these nanoparticles. Here we report the integration of machine learning with high-throughput experimentation to enable the rapid and large-scale identification of such nanoformulations. We identified 100 self-assembling drug nanoparticles from 2.1 million pairings, each including one of 788 candidate drugs and one of 2,686 approved excipients. We further characterized two nanoparticles, sorafenib–glycyrrhizin and terbinafine–taurocholic acid both ex vivo and in vivo. We anticipate that our platform can accelerate the development of safer and more efficacious nanoformulations with high drug-loading capacities for a wide range of therapeutics.
Self-assembly of small drugs with organic dyes represents a facile route to synthesize nanoparticles with high drug-loading capability. Here the authors combine a machine learning approach with high-throughput experimental validation to identify which combinations of drugs and excipient lead to successful nanoparticle formation and characterize the therapeutic efficacy of two of them in vitro and in animal models. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 AUTHOR CONTRIBUTIONS D.R., R.L. and G.T. conceived the study. D.R., Y.R., A.R.K., R.L, and G.T. designed experiments. D.R. and J.W.Y. performed in silico experiments. D.R., R.C., J.W.Y., N.N., R.M.Z., T.E., J.L.H. performed in vitro experiments. D.R., R.C., A.G. performed in vivo experiments. Y.R., A.R.K., T.v.E., A.L.-J., C.K.S., J.H.C supported in vitro experiments. Y.R., A.R.K., E.M.S, D.L, J.C., S.M.T, K.I., P.C. and A.M.H. supported in vivo experiments. D.S.Y. performed TEM imaging and K.H, A.L., J.R. performed pharmaceutical analytics. D.R., R.L. and G.T. wrote the manuscript with contributions from the other authors. All authors approved the final version of this manuscript. |
ISSN: | 1748-3387 1748-3395 1748-3395 |
DOI: | 10.1038/s41565-021-00870-y |